ClinicalTrials.gg
CompletedNCT05726266Updated Oct 16, 2026

Effect and Safety of Listening to Music for Chronic Pain Relief

An interventional study of Music and Audiobook in Chronic Pain, sponsored by Víctor Fernández-Dueñas. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Víctor Fernández-Dueñas · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 174 studies in Chronic Pain with a site in Spain — 34 open to participants now, 40 under way, 1 of them phase 3. Chronic Pain · Spain.

Enrollment
65th of 141
70 · median 66
Started
2023
with 19 others
No phase
126 of 174
23 open now
Registered
108th of 174
by date

Among the 174 studies in Chronic Pain with a site in Spain, this one is the 65th largest by enrollment of the 141 interventional ones that give a count, is one of 20 that started in 2023, is one of 126 with no phase, and was the 108th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

34 of the 174 studies in Chronic Pain with a site in Spain are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Chronic Pain with a site in Spain, or all of them as a file.
02

Study summary

Chronic pain is a multidimensional pathological condition that reduces patients' quality of life and interferes with their daily family and work activities.

Opioids are the most powerful analgesics in the treatment of pain. They are used as a basic analgesic treatment for managing patients with chronic pain and as an analgesic treatment for managing breakthrough pain.

Chronic administration of opioids can cause significant side effects (e.g., dependence, constipation) and tolerance to their analgesic effects, limiting their use. Different behavioral therapies (e.g., mindfulness and cognitive therapy) have been proposed to potentiate the analgesic effects of opioids and, consequently, reduce the dose and the appearance of adverse effects. One of the proposed approaches consists of listening to music therapeutically as a cognitive tool that modulates attention and regulates mood. Some studies provide evidence that music can reduce opioid requirements in patients with chronic pain. On the other hand, both opioids and music activate brain circuits for reward, reinforcement, and motivation.

Preliminary results obtained by our research group in animal models suggest that listening to music can reduce the appearance of a withdrawal syndrome after chronic administration of opioids.

Our working hypothesis is that multimodal therapy, based on listening to music as an adjuvant treatment to regular analgesic treatment with opioids, reduces pain intensity and its harmful effects in patients diagnosed with chronic non-cancer pain. Hence, the daily amount of opioids taken will be reduced, as well as the likelihood of developing opioid tolerance, dependence, and other opioid-related adverse events. At the same time, these patients' emotional well-being and quality of life will improve.

This is a parallel-group, open-label, single-center randomized, pilot, controlled clinical trial that aims to evaluate the effect and safety of music as a coadjuvant treatment for chronic non-cancer pain.

Read the detailed description

Chronic non-cancer pain (CNCP) is defined as pain lasting from three to six months or persisting for longer than expected for tissue healing or underlying disease resolution [López, 2014]. Other authors define it as pain lasting for more than three months, continuously or intermittently, present more than five days a week, with moderate or high intensity on the visual analog scale (VAS), and/or impairing one's functional capacity [Guerra de Hoyos, 2014].

The World Health Organization (WHO) estimates that 20% of the world population suffers from chronic pain to some degree [Turk, 2011]. Moreover, CNCP impacts patients' quality of life substantially, affecting physical and psychosocial dimensions and interfering with daily-life activities. It also poses a heavy burden on health and social security services by increasing healthcare and economic aid demand for lost days at work [Breivik, 2013; Zimmer, 2021; Hopkins, 2022].

The main objective of the treatment is to maintain physical and mental functionality while improving quality of life. This may require a multimodal approach, including, in addition to medication, other interventions such as psychological therapy, active physiotherapy, movement therapy, or percutaneous electrostimulation, among others [Turk; 2011]. However, opioid use has been on the rise in the last few years, and its use is not free from adverse events.

Our working hypothesis is that a multimodal therapy, based on listening to music as a coadjuvant treatment to maintenance analgesic treatment with opioids, reduces pain intensity in patients diagnosed with CNCP. As a result, the daily amount of opioids taken will be reduced, as well as the likelihood of developing opioid tolerance, dependence, and other opioid-related adverse events. At the same time, these patients' emotional well-being and quality of life will improve.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • Music
  • Chronic Pain
  • Chronic Non-Cancer Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ≥18 years of age.
  • Diagnosed with Chronic Non-Oncological Pain.
  • Under regular (maintenance) opioid treatment for at least one month.
  • Patients who sign the written .

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • History of an organic brain disorder or substance abuse/dependence.
  • History of Psychotic disorder, bipolar disorder, and/or intellectual disability.
  • Patients at risk of opioid addiction.
  • Patients that the Pain Clinic physician or psychologist believe will not comply with the study treatment/procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Music Group

    Patients randomized to this group will listen daily to a musical playlist for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.

    Other: Music

  • Placebo comparator
    Audiobooks Group

    Patients randomized to this group will listen to an audiobook daily for 30 - 60 minutes in a row through a mobile device. This will be performed in addition to the opioid treatment.

    Other: Audiobook

Interventions

  • OtherMusic

    Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.

  • OtherAudiobook

    Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.

06

What researchers measure

Primary outcomes

  1. Pain intensity measured by the Visual Analog Scale

    The Visual Analog Scale is a continuous variable on a 10 cm line representing "no pain" (0 cm) to "worst imaginable pain" (10 cm). Pain intensity was also prospectively assessed using an 11-point Numerical Rating Scale (NRS; 0-10), with higher scores indicating greater pain intensity. We will consider as responders those patients with a ≥30% reduction in the "maximum pain intensity in the last 24 hours" at any time during the study compared to the baseline score (study start visit) for at least 3 consecutive days.

    Time frame: 4 weeks

  2. Pain intensity differences from baseline during the 4 weeks of treatment

    We will assess the mean pain intensity differences from baseline during the 4 weeks of treatment. Daily NRS pain-intensity differences from baseline.

    Time frame: 4 weeks

  3. Scores on the Spanish Pain Questionnaire (SPQ)

    The Spanish Pain Questionnaire (SPQ; Cuestionario Español del Dolor) is the Spanish adaptation of the Short-Form McGill Pain Questionnaire, with higher scores indicating greater pain intensity. Changes between the baseline and end-of-treatment scores will be assessed.

    Time frame: 4 weeks

Secondary outcomes

  1. Change in pain intensity considering alternative definitions of responder

    Other definitions of responder will be considered for capturing different response nuances: * Alternative Responder (AR) 1: ≥50% reduction in the "maximum pain intensity (MPI) in the last 24h" at any given time during the study compared to the baseline score for at least 3 consecutive days. * AR2: ≥30% reduction in the "current pain" at any given time during the study compared to the baseline score for at least 3 consecutive days. * AR3: ≥50% reduction in the "current pain" at any given time during the study compared to the baseline score for at least 3 consecutive days. * AR4: ≥30% reduction in the "MPI in the last 24h" AND in the "current pain" at any given time during the study compared to the baseline score for at least 3 consecutive days. * AR5: ≥50% reduction in the "MPI in the last 24h" AND in the "current pain" at any given time during the study compared to the baseline score for at least 3 consecutive days.

    Time frame: 4 weeks

  2. Requirement of rescue analgesia

    As an alternative way of measuring pain intensity. Therefore, we will consider another definition of responder: • Alternative Responder 6: patients who do not require rescue analgesia.

    Time frame: 4 weeks

  3. Change of status according to the Hospital Anxiety and Depression Scale (HADS) scores between the baseline and end-of-treatment visits.

    The Hospital Anxiety and Depression Scale (HADS) is composed of 2 subscales, one for depression and the other for anxiety. Each subscale consists of 7 items; each item score ranges from 0 (best result possible) to 3 (worst result possible). A final subscale score is achieved by summing the items scores. Scores in each subscale ranging from 0 to 7 denote normal levels of anxiety/depression; scores ranging from 8 - 10 denote borderline cases; scores ranging from 11 to 21 denote abnormal cases.

    Time frame: 4 weeks

  4. Mean Total Mood Disturbance (TMD) scores (measured by the Profile of Mood States [POMS]) between the baseline and end-of-treatment visits.

    The Profile of Mood States (POMS) questionnaire assesses six mood subscales: tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion. High vigor scores reflect a good mood or emotion, and low scores in the other subscales reflect a good mood or emotion. The total mood disturbance (TMD) score is computed by adding the five negative subscale scores (tension-anxiety, depression, anger-hostility, vigor, fatigue, and confusion) and subtracting the vigor score. Higher TMD scores indicate a greater degree of mood disturbance.

    Time frame: 4 weeks

  5. Mean change in the Patient Global Impression of Change (PGIC) scores between the baseline and end-of-treatment visits.

    The Patient Global Impression of Change (PGIC) is a self-reported 7-point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."

    Time frame: 4 weeks

  6. Mean change in the Short-Form 36 (SF-36) scores between the baseline and end-of-treatment visits.

    The Short-Form 36 (SF-36) consists of 36 questions meant to reflect 8 domains of health, including physical functioning, physical role, pain, general health, vitality, social function, emotional role, and mental health. Scores range from 0 (maximum disability) to 100 (no disability).

    Time frame: 4 weeks

  7. Change in the EuroQoL - 5 Dimensions - 5 Levels (EQ-5D-5L) scores between the baseline and end-of-treatment visits.

    The EuroQoL - 5 Dimensions - 5 Levels (EQ-5D-5L) comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems (1), slight problems (2), moderate problems (3), severe problems (4), and extreme problems (5). The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: 4 weeks

  8. Number of adverse events by treatment arm.

    Overall number of AEs in each group

    Time frame: 4 weeks

  9. Number of side effects derived from opioid use (UKU scale)

    These will be assessed by the Udvalg für Kliniske Undersøgelser (UKU) Side Effect Rating Scale, a comprehensive rating scale that includes 48 individual side effects that can be grouped into the four main dimensions of psychic, neurological, autonomic and other side effects.

    Time frame: 4 weeks

  10. Number of adverse events related to the treatments under study (music therapy or audiobooks).

    Number of adverse events considered as treatment-emergent adverse events.

    Time frame: 4 weeks

  11. Mean change in the Opioid Risk Tool (ORT) score

    The Opioid Risk Tool (ORT) is a brief, self-report screening tool to assess the risk for opioid abuse among individuals prescribed opioids for treatment of chronic pain. Total scores of 3 or lower indicate low risk for future opioid abuse; 4 to 7 indicate moderate risk; and a score of 8 or higher indicate a high risk.

    Time frame: 4 weeks

  12. Mean change in the Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) questionnaire score.

    The Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) is a 24-question questionnaire created to help determine how much monitoring a patient on long-term opioid therapy might require. Questions are scored form 0 (best result) to 4 (worst result). A total score of 18 or higher is considered positive.

    Time frame: 4 weeks

07

Study locations

1 site
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
08

References and documents

Publications

  • Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011 Jun 25;377(9784):2226-35. doi: 10.1016/S0140-6736(11)60402-9. PubMed 21704872 ↗
  • Zimmer Z, Fraser K, Grol-Prokopczyk H, Zajacova A. A global study of pain prevalence across 52 countries: examining the role of country-level contextual factors. Pain. 2022 Sep 1;163(9):1740-1750. doi: 10.1097/j.pain.0000000000002557. Epub 2021 Dec 15. PubMed 35027516 ↗
  • Hopkins RE, Degenhardt L, Campbell G, Farnbach S, Gisev N. "Frustrated with the whole system": a qualitative framework analysis of the issues faced by people accessing health services for chronic pain. BMC Health Serv Res. 2022 Dec 31;22(1):1603. doi: 10.1186/s12913-022-08946-8. PubMed 36587208 ↗
  • Breivik H, Eisenberg E, O'Brien T; OPENMinds. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health. 2013 Dec 24;13:1229. doi: 10.1186/1471-2458-13-1229. PubMed 24365383 ↗
  • Grau-Sanchez J, Serrano A, Villoria J, Carnaval T, Porto MF, Zapata L, Flores-Garcia M, Segura E, Garrido-Pedrosa J, Rodriguez-Fornells A, Fernandez-Duenas V, Videla S. Effect and safety of listening to music or audiobooks as a coadjuvant treatment for chronic pain patients under opioid treatment: a study protocol for an open-label, parallel-group, randomised, controlled, proof-of-concept clinical trial in a tertiary hospital in the Barcelona South Metropolitan area. BMJ Open. 2023 Sep 11;13(9):e074948. doi: 10.1136/bmjopen-2023-074948. PubMed 37696633 ↗

Individual participant data

Plan to share: Yes — The datasets used or analyzed during the study will be available from the corresponding author on reasonable request.

Supporting information: Study protocol

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Oct 2025, 28 months.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 28 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2024 → Oct 2025 and completion May 2025 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 13, 2023
StartActual
May 18, 2023
Primary completionActual
Oct 16, 2025was Sep 2024
CompletionActual
Oct 16, 2025was May 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital Universitari de Bellvitge · L'Hospitalet de Llobregat, Spain
Show 1 removed
  • Hospital Universitari de Bellvitge · L'Hospitalet De Llobregat, Spain
Oct 16, 2026
Primary completion
Sep 2024→Oct 16, 2025 (actual)
Oct 16, 2026
Study completion
May 2025→Oct 16, 2025 (actual)
Oct 16, 2026
Primary outcomes
1 edited, 2 description edited
What changed in the outcomes
  • EditedScores on the McGill MultidimensionalSpanish Pain Questionnaire (SPQ)Time frame: 4 weeks
  • DescriptionPain intensity differences from baseline during the 4 weeks of treatment: how it is measured was reworded
  • DescriptionPain intensity measured by the Visual Analog Scale: how it is measured was reworded
Oct 16, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37696633 ↗
Oct 16, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange in pain intensity considering alternative definitions of responder (also measured by the Visual Analog Scale)Time frame: 4 weeks
Oct 16, 2026
Sponsor
Sebastian Videla→Víctor Fernández-Dueñas
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37696633 ↗
    1 site added, 1 site removed
    Show site
    • Hospital Universitari de Bellvitge · L'Hospitalet de Llobregat, Spain
    Show 1 removed
    • Hospital Universitari de Bellvitge · L'Hospitalet De Llobregat, Spain
    Primary completion Sep 2024→Oct 16, 2025 (now actual)
    Study completion May 2025→Oct 16, 2025 (now actual)
    Primary outcomes 1 edited, 2 description edited
    What changed in the outcomes
    • EditedScores on the McGill MultidimensionalSpanish Pain Questionnaire (SPQ)Time frame: 4 weeks
    • DescriptionPain intensity differences from baseline during the 4 weeks of treatment: how it is measured was reworded
    • DescriptionPain intensity measured by the Visual Analog Scale: how it is measured was reworded
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in pain intensity considering alternative definitions of responder (also measured by the Visual Analog Scale)Time frame: 4 weeks
    Sponsor Sebastian Videla→Víctor Fernández-Dueñas
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05726266
Lead sponsor
Víctor Fernández-Dueñas
Responsible party
Víctor Fernández-Dueñas (Associate professor, University of Barcelona) — Sponsor-investigator
First posted
Feb 13, 2023
Start date
May 18, 2023
Primary completion
Oct 16, 2025
Completion
Oct 16, 2025
Last update
Oct 16, 2026

Study contacts

Ancor S Alfonso, MD
principal investigator · Anesthesiologist at Bellvitge University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion